Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Front Immunol ; 11: 491, 2020.
Article in English | MEDLINE | ID: mdl-32265934

ABSTRACT

Estrogen contributes to females' strong antibody response to microbial vaccines and proneness to autoimmunity, particularly antibody-mediated systemic autoimmunity, in females. We have hypothesized that this is due to estrogen-mediated potentiation of class switch DNA recombination (CSR) and somatic hypermutation (SHM). As we have shown, estrogen boosts AID expression, which is critical for both CSR and SHM, through upregulation of HoxC4, which together with NF-κB critically mediates Aicda (AID gene) promoter activation. We contend here that additional regulation of Aicda expression by estrogen occurs through epigenetic mechanisms. As we have shown, histone deacetylase inhibitors (HDIs) short-chain fatty acid (SCFA) butyrate and propionate as well as the pharmacologic HDI valproic acid upregulate miRNAs that silence AID expression, thereby modulating specific antibody responses in C57BL/6 mice and autoantibody responses in lupus-prone MRL/Faslpr/lpr mice. Here, using constitutive knockout Esr1-/- mice and B cells as well as conditional knockout Aicdacre/creEsr1flox/flox mice and B cells, we showed that the HDI-mediated downregulation of Aicda expression as well as the maturation of antibody and autoantibody responses is reversed by estrogen and enhanced by deletion of ERα or E2 inhibition. Estrogen's reversion of HDI-mediated inhibition of Aicda and CSR in antibody and autoantibody responses occurred through downregulation of B cell miR-26a, which, as we showed, targets Aicda mRNA 3'UTR. miR-26a was significantly upregulated by HDIs. Accordingly, enforced expression of miR-26a reduced Aicda expression and CSR, while miR-26a-sponges (competitive inhibitors of miR-26a) increased Aicda expression and CSR. Thus, our findings show that estrogen reverses the HDI-mediated downregulation of AID expression and CSR through selective modulation of miR-26a. They also provide mechanistic insights into the immunomodulatory activity of this hormone and a proof-of-principle for using combined ER inhibitor-HDI as a potential therapeutic approach.


Subject(s)
Autoantibodies/biosynthesis , B-Lymphocytes/drug effects , Butyrates/pharmacology , Cytidine Deaminase/biosynthesis , Estradiol/pharmacology , Histone Deacetylase Inhibitors/pharmacology , Immunoglobulin Class Switching/drug effects , Isoantibodies/biosynthesis , MicroRNAs/biosynthesis , Propionates/pharmacology , Valproic Acid/pharmacology , 3' Untranslated Regions , Animals , Autoantibodies/immunology , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Base Sequence , Binding, Competitive , Cytidine Deaminase/deficiency , Cytidine Deaminase/genetics , Down-Regulation/drug effects , Estrogen Receptor alpha/deficiency , Female , Gene Expression Regulation/drug effects , Humans , Immunoglobulin Class Switching/genetics , Isoantibodies/immunology , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/immunology , Mice , Mice, Inbred MRL lpr , Mice, Knockout , MicroRNAs/antagonists & inhibitors , MicroRNAs/genetics , Phosphoprotein Phosphatases/genetics , Phosphoric Monoester Hydrolases/genetics , Promoter Regions, Genetic , Proof of Concept Study , Recombinant Proteins/metabolism , Sequence Alignment , Sex Characteristics , Transduction, Genetic
2.
Nat Commun ; 11(1): 60, 2020 01 02.
Article in English | MEDLINE | ID: mdl-31896754

ABSTRACT

Short-chain fatty acids (SCFAs) butyrate and propionate are metabolites from dietary fiber's fermentation by gut microbiota that can affect differentiation or functions of T cells, macrophages and dendritic cells. We show here that at low doses these SCFAs directly impact B cell intrinsic functions to moderately enhance class-switch DNA recombination (CSR), while decreasing at higher doses over a broad physiological range, AID and Blimp1 expression, CSR, somatic hypermutation and plasma cell differentiation. In human and mouse B cells, butyrate and propionate decrease B cell Aicda and Prdm1 by upregulating select miRNAs that target Aicda and Prdm1 mRNA-3'UTRs through inhibition of histone deacetylation (HDAC) of those miRNA host genes. By acting as HDAC inhibitors, not as energy substrates or through GPR-engagement signaling in these B cell-intrinsic processes, these SCFAs impair intestinal and systemic T-dependent and T-independent antibody responses. Their epigenetic impact on B cells extends to inhibition of autoantibody production and autoimmunity in mouse lupus models.


Subject(s)
Antibodies/genetics , Epigenesis, Genetic/drug effects , Fatty Acids, Volatile/pharmacology , Gastrointestinal Microbiome/immunology , Animals , Antibodies/immunology , Antibodies/metabolism , Autoantibodies/genetics , Autoantibodies/immunology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Butyrates/pharmacology , Cytidine Deaminase/antagonists & inhibitors , Cytidine Deaminase/genetics , Cytidine Deaminase/immunology , Cytidine Deaminase/metabolism , Dietary Fiber , Fatty Acids, Volatile/isolation & purification , Fatty Acids, Volatile/pharmacokinetics , Female , Gastrointestinal Microbiome/drug effects , Gastrointestinal Microbiome/genetics , Histone Deacetylase Inhibitors/immunology , Histone Deacetylase Inhibitors/pharmacology , Humans , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/immunology , Mice, Inbred C57BL , Mice, Mutant Strains , Positive Regulatory Domain I-Binding Factor 1/antagonists & inhibitors , Positive Regulatory Domain I-Binding Factor 1/genetics , Positive Regulatory Domain I-Binding Factor 1/immunology , Positive Regulatory Domain I-Binding Factor 1/metabolism , Propionates/pharmacology , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL